Vor Biopharma Inc.
VOR
$0.01
Change (1 day)
$3.14
Year High
$0.63
Year Low
Categories
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Vor Biopharma Inc. (VOR) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 4.3 M | 59.1 M | 209.83 M | 140.8 M | |
| 2022 | -18,794,000 | 48.76 M | 299.37 M | 236.95 M | |
| 2021 | -101,788,000 | 26.33 M | 242.59 M | 214.4 M | |
| 2020 | -30,246,000 | 27.64 M | 75.91 M | 49.11 M | |
| 2019 | -6,466,000 | 2.19 M | 9.83 M | 7.54 M |